Endogenous stimuli-responsive nanoparticles for cancer therapy: From bench to bedside

Feiyu Xie; Mina Wang; Qishuang Chen; Tiange Chi; Shijie Zhu; Peng Wei; Yingying Yang; Le Zhang; Xuexin Li; Zehuan Liao

doi:10.1016/j.phrs.2022.106522

Endogenous stimuli-responsive nanoparticles for cancer therapy: From bench to bedside

Pharmacol Res. 2022 Dec:186:106522. doi: 10.1016/j.phrs.2022.106522. Epub 2022 Oct 23.

Authors

Feiyu Xie¹, Mina Wang², Qishuang Chen³, Tiange Chi⁴, Shijie Zhu⁵, Peng Wei⁶, Yingying Yang⁷, Le Zhang⁸, Xuexin Li⁹, Zehuan Liao¹⁰

Affiliations

¹ Graduate School, Beijing University of Chinese Medicine, Beijing 100029, China; Oncology Department, Wangjing Hospital of China Academy of Chinese Medical Sciences, Beijing 100102, China.
² Graduate School, Beijing University of Chinese Medicine, Beijing 100029, China; Department of Acupuncture and Moxibustion, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing Key Laboratory of Acupuncture Neuromodulation, Beijing 100010, China.
³ Graduate School, Beijing University of Chinese Medicine, Beijing 100029, China; Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing 100029, China.
⁴ Key Laboratory of Growth Regulation and Translational Research of Zhejiang Province, School of Life Sciences, Westlake University, Zhejiang 310024, China.
⁵ Oncology Department, Wangjing Hospital of China Academy of Chinese Medical Sciences, Beijing 100102, China.
⁶ School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 100029, China.
⁷ Clinical Research Center, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternaity and Infant Hospital, School of Medicine, Tongji University, Shanghai 201204, China.
⁸ Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Solna 17165, Sweden.
⁹ Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Solna 17165, Sweden. Electronic address: Xuexin.li@ki.se.
¹⁰ School of Biological Sciences, Nanyang Technological University, Singapore 637551, Singapore; Department of Microbiology, Tumor, and Cell Biology (MTC), Karolinska Institutet, Stockholm 17177, Sweden. Electronic address: Liao0058@e.ntu.edu.sg.

PMID: 36283629
DOI: 10.1016/j.phrs.2022.106522

Abstract

Cancer is complicated to treat because of its high propensity for recurrence and metastasis, and various side effects of conventional cancer treatments. With the development of nanotechnology, biology, material science and pharmacy, nanoparticles emerge as a promising method to load anti-cancer drugs to deal with the downsides of conventional treatments. Among the various class of nanoparticles, endogenous stimuli-responsive nanoparticles exert significant anti-cancer effects by releasing drugs due to the stimulations from pH gradient, redox as well as other enzymes of cancer microenvironment. Extraordinary progress has been achieved as the latest endogenous stimuli-responsive nanoparticles exhibit better therapeutic effects, lower toxicity, and superior biocompatibility, indicating brighter prospects for cancer therapy. However, these stimuli-responsive nanoparticles are still not ready for large-scale clinical application, due to reasons such as the lack of clinical trials and high cost of manufacturing. Here, we consolidate the advancements and limitations of various endogenous stimuli-responsive nanoparticles, as well as critically discuss the prospects of this kind of nanoparticles in tumor treatments.

Keywords: Cancer; Endogenous-stimuli responsive nanoparticles; Nanocarrier; Targeted therapy; Tumor microenvironment.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents* / pharmacology
Antineoplastic Agents* / therapeutic use
Drug Carriers / therapeutic use
Drug Delivery Systems
Humans
Nanoparticles* / therapeutic use
Nanotechnology
Neoplasms* / drug therapy
Tumor Microenvironment

Substances

Antineoplastic Agents
Drug Carriers